CRGX vs. ACLX, ADMA, APGE, IOVA, VCEL, CGON, IMCR, RXRX, KYMR, and BEAM
Should you be buying CARGO Therapeutics stock or one of its competitors? The main competitors of CARGO Therapeutics include Arcellx (ACLX), ADMA Biologics (ADMA), Apogee Therapeutics (APGE), Iovance Biotherapeutics (IOVA), Vericel (VCEL), CG Oncology (CGON), Immunocore (IMCR), Recursion Pharmaceuticals (RXRX), Kymera Therapeutics (KYMR), and Beam Therapeutics (BEAM). These companies are all part of the "biological products, except diagnostic" industry.
Arcellx (NASDAQ:ACLX) and CARGO Therapeutics (NASDAQ:CRGX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations.
In the previous week, CARGO Therapeutics had 6 more articles in the media than Arcellx. MarketBeat recorded 9 mentions for CARGO Therapeutics and 3 mentions for Arcellx. CARGO Therapeutics' average media sentiment score of 1.77 beat Arcellx's score of 1.03 indicating that Arcellx is being referred to more favorably in the media.
Arcellx presently has a consensus price target of $78.00, indicating a potential upside of 43.75%. CARGO Therapeutics has a consensus price target of $29.00, indicating a potential upside of 65.71%. Given Arcellx's higher possible upside, analysts clearly believe CARGO Therapeutics is more favorable than Arcellx.
Arcellx received 41 more outperform votes than CARGO Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CARGO Therapeutics an outperform vote while only 77.05% of users gave Arcellx an outperform vote.
Arcellx has higher revenue and earnings than CARGO Therapeutics.
CARGO Therapeutics has a net margin of 0.00% compared to CARGO Therapeutics' net margin of -38.39%. Arcellx's return on equity of 0.00% beat CARGO Therapeutics' return on equity.
96.0% of Arcellx shares are owned by institutional investors. Comparatively, 93.2% of CARGO Therapeutics shares are owned by institutional investors. 6.2% of Arcellx shares are owned by insiders. Comparatively, 1.4% of CARGO Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Arcellx beats CARGO Therapeutics on 9 of the 15 factors compared between the two stocks.
Ad DTI
Most people would never touch this orange powder… would you?
At first glance, it looks like some ordinary “orange” powder…
But in reality, it is a scientific breakthrough in energy technology.
One that could wipe out fossil fuel, coal, and even the “glorified” renewable energy in just a few years.
And right now, governments, institutions, and the elites are jumping on this resource at record pace to the point where we’re starting to run out.
The question is…
Why are the top 1% piling in this much?
And more importantly, what will be the implications of this act by the elites on YOU and of course, the stock market?
Well, all the answers you need are right here
Get CARGO Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CARGO Therapeutics Competitors List
Related Companies and Tools
